Dose De-escalation and Sentinel LN Mapping Driven Radiotherapy of Contralateral Neck in Ipsilateral Node Positive HNSCC (SEMIRAHN)
Squamous Cell Carcinoma of Head and Neck
About this trial
This is an interventional treatment trial for Squamous Cell Carcinoma of Head and Neck focused on measuring HNSCC, Dose and Volume de-escalation in radiotherapy, sentinel lymph nodes mapping
Eligibility Criteria
Inclusion Criteria:
- Written informed consent given according to ICH/GCP and national/local regulations must be obtained prior to any screening procedures.
- World Health Organization (WHO) performance status 0-1.
- Age ≥ 18 years.
- Patients with a pathologically proven invasive HNSCC, including oral cavity, oropharynx (independently of HPV status), larynx or hypopharynx.
- Decision by Multidisciplinary Tumor Board of primary treatment with radical radiotherapy with or without concurrent chemotherapy (according to the local guidelines).
Baseline imaging of the neck:
- a. ≤ 2.5 mm slices CT with iodine injection (independently or during the FDG-PET/CT examination IF acquired in normal diagnostic conditions, i.e. arms along the thorax with diagnostic quality);
- b. MRI not mandatory but allowed, performed according to centres guidelines;
- c. FDG-PET/CT.
Tumor characteristics:
- cT-classification (8th TNM staging): T1(except T1 of glottis)-T3.
- cN-classification (8th TNM staging), as assessed by iodine contrasted CT (or MRI) and FDG-PET:
i. mandatorily cN0 contralaterally to the primary tumor (or on one side of the neck for midline primary tumors):
1. smallest diameter < 5 mm in retropharyngeal level (VIIa); 2. smallest diameter of Küttner node (level IIa) < 12 mm; 3. smallest diameter < 10 mm or sum of smallest and largest diameters < 17 mm in any other level; 4. no central necrosis ; 5. maximal standardized uptake value (SUVmax) ≤ 2.2; 6. in dubious cases (typically 2.2 < SUVmax < 4.5 and inconclusive CT or MRI), US-guided FNAC may be required to exclude positive node contralaterally.
ii. ipsilaterally positive (if any of the above mentioned criteria is met). c. No distant metastasis.
Exclusion Criteria:
Patient has history of:
- radiotherapy or surgery in the neck with potential impact on lymphatic drainage ("violated neck");
- cancer in the last five years (excluding skin basal cell carcinoma and in situ cervix carcinoma);
- Absolute contra-indication to iodine contrast injection, even after proper cortisone and cetirizine pre-medication.
- HNSCC from nose, sinuses, oesophagus, salivary glands or nasopharynx.
- Non-HNSCC histology.
- Positive contralateral neck by node size or positive US-FNAC in dubious nodes.
- Synchronous second malignancy.
- Distant metastasis.
- Tumor crossing the midline without contralateral mapping after 99mTc-nanocolloïd injection.
- Any psychological disorder or familial, sociological or geographical condition which, in the investigator's opinion, might jeopardise participant's safety or compliance with the protocol.
- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method.
Highly effective methods of birth control are defined as those, alone or in combination, that result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatments) or vasectomised partner.
Sites / Locations
- ZOLRecruiting
- Jessa ZiekenhuisRecruiting
- OLV AalstRecruiting
- UCL Saint-LucRecruiting
- Institute Jules BordetRecruiting
- University Hospital GentRecruiting
- Universitaire Ziekenhuizen LeuvenRecruiting
- AZ Sint-MaartenRecruiting
- CHU-UCL NamurRecruiting
- AZ TurnhoutRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Arm A: Unilateral RT
Arm B: Whole level
Arm C: SLN alone
If SPECT/CT shows ipsilateral drainage and the tumor does not cross the midline, the subject will automatically be assigned to Arm A, and will receive ipsilateral Radiotherapy with reduced prophylactic dose outside of the macroscopically involved nodes. The contralateral side of the neck will be spared according to the absence of sentinel lymph node drainage.
If SPECT/CT shows contralateral drainage, the subject will be randomized between 'Whole level' and 'SLN alone'. Arm B 'Whole Level': on the contralateral side of the neck, the whole level(s) containing the draining sentinel lymph node(s) will be irradiated at the reduced prophylactic dose. The ipsilateral side of the neck will be irradiated conform to arm A.
If SPECT/CT shows contralateral drainage, the subject will be randomized between 'Whole level' and 'SLN alone'. Arm C 'SLN alone': on the contralateral side of the neck, only the sentinel node(s) will be irradiated at the reduced prophylactic dose. The ipsilateral side of the neck will be irradiated conform to arm A.